Clinical Trials on Early Intervention in Czechia

Total 28 results

Masaryk Memorial Cancer Institute

Completed

Adjuvant Partial-breast Irradiation Using Stereotactic Body Radiation Therapy

Early-stage Breast Cancer

Czechia
Kamil Novobílský

Completed

Verification of the Safety of Early Discharge in Patients After Acute ST-segment Myocardial Infarction

Coronary Artery Disease | Primary Percutaneous Coronary Intervention | Early Discharge | Acute Myocardial Infarction With ST-segment Elevation

Czechia
University of Ostrava

Recruiting

Preventive Intervention to Promote Healthy Ageing

Preventive Intervention

Czechia
Samsung Bioepis Co., Ltd.

Completed

A Study to Compare the Effect of SB3 and Herceptin® in Women With HER2 Positive Breast Cancer

HER2 Positive Early or Locally Advanced Breast Cancer

Czechia
Rottapharm Biotech

Completed

A Study of the EP4 Antagonist CR6086 in Combination With Methotrexate, in DMARD-naïve Patients With Early Rheumatoid Arthritis

Rheumatoid Arthritis, DMARD-naive and Early Disease Patients

Czechia
Alzheon Inc.

Active, not recruiting

Biomarker Effects of ALZ-801 in APOE4 Carriers With Early Alzheimer's Disease

Early Alzheimer's Disease

Netherlands, Czechia
Zuyderland Medisch Centrum
Radboud University Medical Center; Maastricht University Medical Center; Brno... and other collaborators

Recruiting

FFR Driven Complete Revascularization Versus Usual Care in NSTEMI Patients and Multivessel Disease (SLIM)

Coronary Artery Disease | Percutaneous Coronary Intervention | NSTEMI - Non-ST Segment Elevation MI | Myocardial Revascularization | Fractional Flow Reserve, Myocardial

Czechia, Netherlands, Hungary
Masaryk University

Unknown

Comparison of Biolimus A9 and Everolimus Drug-Eluting Stents in Patients With ST Segment Elevation Myocardial Infarction (ROBUST)

Coronary Heart Disease | Percutaneous Coronary Intervention

Czech Republic
Pfizer

Completed

A Study Of PF-05280014 Or Trastuzumab Plus Taxotere® And Carboplatin In HER2 Positive Breast Cancer In The Neoadjuvant Setting (REFLECTIONS B327-04)

Early Breast Cancer

Czechia, Serbia, Slovakia, United States, Belarus, Hungary, Ukraine, Italy, Poland, Russian Federation
Boehringer Ingelheim

Completed

Efficacy, Safety, Tolerability of Pramipexol ER Versus Pramipexol IR Versus Placebo in Early PD Patients

Early Parkinson Disease (Early PD)

United States, Argentina, Austria, Czech Republic, Finland, Germany, Hungary, India, Japan, Malaysia, Russian Federation, Slovakia, Taiwan, Ukraine
Hoffmann-La Roche

Completed

A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer (FeDeriCa)

Early Breast Cancer

France, Spain, United States, Korea, Republic of, Canada, United Kingdom, Argentina, Belgium, Germany, Italy, Taiwan, Thailand, Japan, Brazil, Mexico, Czechia, Poland, Russian Federation, Ukraine
Janssen Scientific Affairs, LLC
Bayer

Completed

A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention (PIONEER AF-PCI)

Atrial Fibrillation | Percutaneous Coronary Intervention

United States, France, Poland, Ukraine, United Kingdom, Belgium, Germany, Taiwan, Argentina, Mexico, Bulgaria, Malaysia, Romania, Russian Federation, South Africa, Turkey, Korea, Republic of, Australia, Canada, Netherlands, Denmark and more
Boehringer Ingelheim

Completed

Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI)

Atrial Fibrillation | Percutaneous Coronary Intervention

Canada, United States, Spain, Korea, Republic of, Australia, Germany, Taiwan, Hong Kong, Thailand, United Kingdom, Turkey, Netherlands, Ireland, Hungary, Croatia, Colombia, Israel, Singapore, Italy, New Zealand, Greece, Mexico, Norway, Swed... and more
PRInnovation GmbH
Julius Clinical; Federal Agency for Disruptive Innovation - SPRIN-D; Priavoid

Recruiting

Study to Assess Safety and Efficacy of PRI-002 in Patients With MCI to Mild Dementia Due to Alzheimer's Disease (AD) (PRImus-AD)

Mild Cognitive Impairment Due to Alzheimer's Disease | Alzheimer's Disease, Early Onset

Germany, Spain, Italy, Czechia, Netherlands, Poland
Alzheon Inc.

Enrolling by invitation

Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects (APOLLOE4-LTE)

Early Alzheimer's Disease

United States, Spain, Canada, Netherlands, Czechia, United Kingdom, France, Germany, Iceland
Hoffmann-La Roche

Recruiting

A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)

Early Breast Cancer

United States, France, Korea, Republic of, Spain, China, Italy, Taiwan, Sweden, Czechia, Hungary, Japan, Greece, Ukraine, Australia, Brazil, Canada, Mexico, Belgium, Argentina, Chile, Serbia, Colombia, Ireland, Hong Kong, Austria, North Macedonia and more
AbbVie (prior sponsor, Abbott)

Completed

Study to Determine the Effects of Different Doses of Methotrexate (MTX) When Taken With Adalimumab in Subjects With Early Rheumatoid Arthritis (RA) (CONCERTO)

Early Rheumatoid Arthritis

United States, Argentina, Austria, Belgium, Canada, Czech Republic, Germany, Poland, Puerto Rico, Spain
AstraZeneca

Recruiting

A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy (CAMBRIA-1)

Breast Cancer, Early Breast Cancer

United States, Canada, United Kingdom, China, Argentina, Australia, Hungary, Netherlands, Korea, Republic of, France, Germany, Italy, Belgium, Bulgaria, India, Mexico, Spain, Vietnam, Colombia, Japan, Peru, Brazil, Malaysia, Taiwan, Tha... and more
Alzheon Inc.
National Institute on Aging (NIA)

Active, not recruiting

An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects (APOLLOE4)

Early Alzheimer's Disease

United States, Spain, Canada, Netherlands, Czechia, United Kingdom, France, Germany, Iceland
AbbVie (prior sponsor, Abbott)

Completed

Efficacy and Safety of Adalimumab and Methotrexate (MTX) Versus MTX Monotherapy in Subjects With Early Rheumatoid Arthritis (PREMIER)

Early Rheumatoid Arthritis

United States, Australia, Austria, Belgium, Canada, Czech Republic, Denmark, Finland, France, Germany, Ireland, Italy, Netherlands, Norway, Slovakia, Spain, Sweden, Switzerland, United Kingdom
Population Health Research Institute

Completed

A Trial of Routine Aspiration Thrombectomy With Percutaneous Coronary Intervention (PCI) Versus PCI Alone in Patients With ST-Segment Elevation Myocardial Infarction (STEMI) Undergoing Primary PCI (TOTAL)

ST Elevation Myocardial Infarction | Acute Coronary Syndrome | Percutaneous Coronary Intervention

Canada, United States, Korea, Republic of, United Kingdom, Spain, New Zealand, France, Greece, Austria, Netherlands, Germany, Finland, Serbia, Czech Republic, Australia, Hungary, Brazil, Belgium, China, Macedonia, The Former Yugoslav...
AstraZeneca
Austrian Breast and Colorectal Cancer Study Group (ABCSG)

Recruiting

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) (CAMBRIA-2)

Breast Cancer, Early Breast Cancer

United States, Spain, Italy, Korea, Republic of, Belgium, Canada, Poland, Portugal, United Kingdom, France, China, Germany, Japan, Mexico, Thailand, Hungary, Australia, Austria, Brazil, Colombia, Taiwan, Malaysia, Philippines, Romania, ... and more
UCB Pharma

Completed

An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Early-Stage Parkinson's Disease

Early Stage Parkinson's Disease

Poland, United Kingdom, Germany, Spain, Switzerland, Belgium, South Africa, New Zealand, Czech Republic, Austria, Hungary, Australia, Italy, Israel, Sweden, Norway, Croatia, Netherlands, Finland, France
Novo Nordisk A/S

Active, not recruiting

A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)

Early Alzheimer´s Disease

Canada, United States, Taiwan, Netherlands, United Kingdom, Spain, Austria, Korea, Republic of, Portugal, Italy, Australia, Argentina, Hungary, Germany, Brazil, China, Poland, Denmark, Czechia, Ireland, Japan, South Africa, Romania, S... and more
Novo Nordisk A/S

Active, not recruiting

A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)

Early Alzheimer's Disease

Canada, United States, Spain, Netherlands, United Kingdom, Austria, Korea, Republic of, Portugal, Italy, Australia, Argentina, Hungary, Germany, Brazil, Poland, Denmark, Czechia, Ireland, Norway, Japan, Romania, South Africa, Sweden, ... and more
Solvay Pharmaceuticals

Completed

An Open Label SLV308 Safety Extension to Study S308.3.003 in Early PD Patients

Early Stage Parkinson's Disease

United States, Australia, Czech Republic, Estonia, Germany, India, Italy, Lithuania, Malaysia, Netherlands, Poland, Portugal, South Africa, Taiwan, Thailand
Solvay Pharmaceuticals

Completed

SLV 308 and Pramipexole for Treatment of Patients With Early Parkinson Disease

Early Stage Parkinson Disease

United States, Australia, Czech Republic, Estonia, France, Germany, India, Italy, Lithuania, Malaysia, Netherlands, Poland, Portugal, South Africa, Spain, Taiwan, Thailand, United Kingdom
Cogentus Pharmaceuticals

Terminated

Clopidogrel and the Optimization of Gastrointestinal Events (COGENT-1) (COGENT-1)

Myocardial Infarction | Coronary Artery Disease | Acute Coronary Syndrome | Percutaneous Coronary Intervention

United States, France, Canada, Australia, Poland, Germany, Italy, Mexico, Romania, Slovakia, Hungary, Czech Republic, Chile, Bulgaria, Puerto Rico, Ukraine

Clinical Trials on Early Intervention in Czechia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in South Korea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations